• Psoriasis

Bryhali Generic Name & Formulations

General Description

Halobetasol propionate 0.01%; lotion.

Pharmacological Class


How Supplied


Generic Availability


Bryhali Indications


Plaque psoriasis.

Bryhali Dosage and Administration


≥18yrs: apply a thin layer to affected areas once daily; max 50g/week. Treatment lasting >8 weeks: not recommended. Discontinue when control is achieved. Do not occlude.


<18yrs: not established.

Bryhali Contraindications

Not Applicable

Bryhali Boxed Warnings

Not Applicable

Bryhali Warnings/Precautions


Not for oral, ophthalmic, or intravaginal use. Avoid use on the face, groin, or axillae. Risk of HPA axis suppression with high-potency corticosteroids, prolonged use, application to large surface areas, occlusive use, altered skin barrier, concomitant multiple corticosteroid-containing products, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Treat infection if present; discontinue until resolved. Reevaluate periodically. Discontinue if allergic contact dermatitis occurs. Pregnancy. Nursing mothers: avoid nipple/areola area due to infant exposure.

Bryhali Pharmacokinetics

See Literature

Bryhali Interactions

Not Applicable

Bryhali Adverse Reactions

Adverse Reactions

Upper respiratory tract infection, application site dermatitis, hyperglycemia; local adverse reactions (eg, atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, miliaria), Cushing’s syndrome, glucosuria, HPA axis suppression (esp. in children).

Bryhali Clinical Trials

See Literature

Bryhali Note

Not Applicable

Bryhali Patient Counseling

See Literature